Pentecam gives accurate measurements

Article

The Pentecam is reliable in measuring superior and inferior anterior chamber angle (ACA) temporal and nasal ACA, anterior chamber volume (ACV) and anterior chamber depth (ACD).

The Pentecam is reliable in measuring superior and inferior anterior chamber angle (ACA) temporal and nasal ACA, anterior chamber volume (ACV) and anterior chamber depth (ACD).

Dr Gemma C.M. Rossi et al., University Eye Clinic of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, completed an observational, single-centre, cross-sectional investigation on 28 eyes with primary narrow-angle or primary angle-closure glaucoma and 36 controls.

All patients underwent gonioscopy and measurements for ACA, ACV and ACD. Receiver operating characteristics (ROC) curves analysis was used to assess the validity of Pentecam parameters.

According to the ROC analysis, there was a high discriminate power for all Pentecam measures and the chosen cutoff values enabled the correct identification of narrow angles.

Overall, the Pentecam is efficient in detecting occludable angles it is non-contact, meaning it provides parameters in a short time period, representing a possible screening tool.

The abstract can be viewed in the

latest European Journal of Ophthalmology

.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.